Bio-Rad Laboratories stock holds on to year-end earnings context

Bio-Rad Laboratories, Inc. stock remains anchored by its latest reported fundamentals, including fiscal 2025 revenue, operating profitability, and cash generation, while the shares trade against a still-evolving market backdrop. The companys ISIN is US09062X1037, and the investment case continues to be framed by the most recent annual figures and the next earnings cycle.

Fiscal 2025 sets the base

Bio-Rad Laboratories, Inc. reported fiscal 2025 revenue of $2.56 billion, compared with $2.57 billion in fiscal 2024, showing that the top line was broadly flat year over year. The company also reported a full-year non-GAAP gross margin of 55.2% in fiscal 2025, a metric that matters for the operating leverage investors track most closely.

Net cash provided by operating activities reached $535.8 million in fiscal 2025, giving the business a sizable internal funding base for research, manufacturing, and capital spending. That cash figure is useful because it connects earnings quality with balance-sheet flexibility, not just headline revenue.

Margin and cash matter

Bio-Rad Laboratories also reported fiscal 2025 non-GAAP diluted net income per share of $15.37, up from $14.03 in fiscal 2024. That 9.5% increase is a clearer comparison than revenue alone, because it shows earnings per share rising even as sales were nearly unchanged.

The same annual report showed non-GAAP operating income of $394.5 million in fiscal 2025. Against revenue of $2.56 billion, that implies an operating profile that is still sensitive to mix, volume, and cost discipline.

Bio-Rad Laboratories stock and the product mix

Bio-Rad Laboratories builds its business around life science research and clinical diagnostics, with revenue tied to products used in laboratories and medical testing workflows. That mix matters because it links recurring consumable demand, instrument placements, and customer spending cycles to the annual numbers already reported.

The companys reported 2025 figures suggest that Bio-Rad Laboratories stock is being valued more on earnings resilience and cash conversion than on rapid sales growth. A revenue base of $2.56 billion, operating income of $394.5 million, and operating cash flow of $535.8 million form the core numeric backdrop.

Market price still defines the next step

Bio-Rad Laboratories stock trades on the New York Stock Exchange under the ticker NYSE: BIO. The closing price line is not included here because this article is built from the available reported company figures and investor materials, not from a dated market quote page.

For readers tracking the shares, the key near-term question is whether future updates can push revenue beyond the $2.56 billion fiscal 2025 level while preserving the 55.2% non-GAAP gross margin and the $535.8 million operating cash flow base. Those three figures set the benchmark now.